Finance

Lists
WUXI06:BKK
Wuxi Biologics (Cayman) Inc. KKPS DR
฿5,20
0,00%
(0,00) 1D
15 ຕ.ລ., 16 ໂມງ 40 ນາທີ 00 ວິນາທີ GMT+7  ·   THB
All symbols
SymbolPriceChange% Change
Generating top insights for WUXI06...
Open
฿5,25
High
฿5,35
Low
฿5,05
Mkt. cap
200,24 ຕື້
Avg. vol.
93,60 ພັນ
Volume
288,50 ພັນ
52-wk high
฿6,25
52-wk low
฿3,02
Shares outstanding
4,12 ຕື້
No. of employees
15 ພັນ
Open
฿5,25
High
฿5,35
Low
฿5,05
Mkt. cap
200,24 ຕື້
Avg. vol.
93,60 ພັນ
Volume
288,50 ພັນ
52-wk high
฿6,25
52-wk low
฿3,02
Shares outstanding
4,12 ຕື້
No. of employees
15 ພັນ
News stories
From web sources and news partners
Profile
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development. WuXi Biologics' roots date back to 2010, when it was founded as a division of WuXi AppTec and began building out capabilities and facilities required for biologics discovery, development and good manufacturing practices. After being spun off from its parent, WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017. As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore. In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong. In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
About Wuxi Biologics (Cayman) Inc. KKPS DR
CEOZhisheng Chen
Employees14,7 ພັນ
Founded2010
Headquarters-
SectorHealth care
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
ກ.ຍ. 2025
ທ.ວ. 2025
ມ.ນ. 2026
ມິ.ຖ. 2026
Revenue
5,92 ຕື້
5,92 ຕື້
5,89 ຕື້
5,89 ຕື້
Cost of goods sold
3,04 ຕື້
3,04 ຕື້
3,17 ຕື້
3,17 ຕື້
Cost of revenue
3,04 ຕື້
3,04 ຕື້
3,17 ຕື້
3,17 ຕື້
Research and development expenses
254,93 ລ້ານ
254,93 ລ້ານ
215,11 ລ້ານ
215,11 ລ້ານ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
631,03 ລ້ານ
631,03 ລ້ານ
591,61 ລ້ານ
591,61 ລ້ານ
Operating expense
921,71 ລ້ານ
921,71 ລ້ານ
860,09 ລ້ານ
860,09 ລ້ານ
Total operating expenses
3,96 ຕື້
3,96 ຕື້
4,03 ຕື້
4,03 ຕື້
Operating income
1,96 ຕື້
1,96 ຕື້
1,86 ຕື້
1,86 ຕື້
Other non operating income
33,58 ລ້ານ
33,58 ລ້ານ
42,20 ລ້ານ
42,20 ລ້ານ
EBT including unusual items
1,96 ຕື້
1,96 ຕື້
1,71 ຕື້
1,71 ຕື້
EBT excluding unusual items
1,94 ຕື້
1,94 ຕື້
1,70 ຕື້
1,70 ຕື້
Income tax expense
476,10 ລ້ານ
476,10 ລ້ານ
251,54 ລ້ານ
251,54 ລ້ານ
Effective tax rate
24,24%
24,24%
14,71%
14,71%
Other operating expenses
-
-
-
-
Net income
1,28 ຕື້
1,28 ຕື້
1,22 ຕື້
1,22 ຕື້
Net profit margin
21,70%
21,70%
20,70%
20,70%
Earnings per share
-
-
-
-
Interest and investment income
115,29 ລ້ານ
115,29 ລ້ານ
106,38 ລ້ານ
106,38 ລ້ານ
Interest expense
-29,76 ລ້ານ
-29,76 ລ້ານ
-22,28 ລ້ານ
-22,28 ລ້ານ
Net interest expenses
85,53 ລ້ານ
85,53 ລ້ານ
84,10 ລ້ານ
84,10 ລ້ານ
Depreciation and amortization charges
-
-
-
-
EBITDA
2,24 ຕື້
2,24 ຕື້
2,27 ຕື້
2,27 ຕື້
Gain or loss from assets sale
317,34 ລ້ານ
317,34 ລ້ານ
-
-
AI content may include mistakes. Learn more
ແອັບຂອງ Google